The 3rd European Iron Academy (EIA) took place on the 12th and 13th September 2016 in Berlin, Germany, and brought together over 450 clinicians with an interest in iron deficiency.
Iron deficiency is the most common nutritional disorder in the world and is the leading cause of anaemia. The condition occurs frequently across multiple therapeutic areas e.g. in patients with chronic diseases such as inflammatory bowel disease, heart failure and chronic kidney disease. In such conditions, inadequately managed iron deficiency has been associated with poor patient outcomes, including increased hospitalisations, reduced quality of life and even higher mortality rates.
The 3rd EIA had the goal of further raising awareness of iron deficiency and stimulating discussion amongst peers, helping them to better understand the causes, the need for improved diagnosis and the current treatment options for their patients.
The 2016 programme offered delegates the opportunity to tailor the sessions to their own clinical interests/areas of expertise; engage in interactive patient case scenarios and breakout sessions; and discuss current standards in iron deficiency management with experts in Q&A-style sessions.
The 3rd EIA is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide participants with CME credits, and is supported by an educational grant from Vifor Pharma.
“We are delighted to be running the 3rd EIA this year, which specifically addresses the need for continuing medical education on iron deficiency,” said Professor Stefan Anker (Germany), EIA 2016 co-Chair and Professor of Innovative Clinical Trials (Cardiology & Cachexia Research) at the University Medical Center Göttingen, Germany.
“This year’s programme will review the latest data relating to the diagnosis and treatment of iron deficiency within a number of key therapy areas, including cardiology, gastroenterology, nephrology and haematology, and showcases the EIA’s all-encompassing approach to education and improving patient outcomes in many disease areas.”
European Iron Academy (EIA)